Asterias Biotherapeutics Inc (NYSE:AST) has earned a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.
Brokers have set a 12 month consensus target price of $8.88 for the company and are predicting that the company will post ($0.16) EPS for the current quarter, according to Zacks. Zacks has also given Asterias Biotherapeutics an industry rank of 110 out of 265 based on the ratings given to related companies.
Several research firms have recently commented on AST. HC Wainwright set a $12.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Wednesday, October 25th.
Several hedge funds and other institutional investors have recently made changes to their positions in AST. Teachers Advisors LLC lifted its stake in shares of Asterias Biotherapeutics by 13.1% in the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 6,714 shares during the period. State Street Corp increased its holdings in Asterias Biotherapeutics by 24.1% during the 2nd quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock valued at $1,169,000 after acquiring an additional 63,773 shares in the last quarter. California State Teachers Retirement System increased its holdings in Asterias Biotherapeutics by 4.6% during the 2nd quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Family Management Corp increased its holdings in Asterias Biotherapeutics by 15.6% during the 2nd quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 6,416 shares in the last quarter.
Shares of Asterias Biotherapeutics (AST) traded down $0.10 during trading hours on Monday, reaching $2.45. 125,033 shares of the company were exchanged, compared to its average volume of 233,698. Asterias Biotherapeutics has a 12-month low of $2.25 and a 12-month high of $5.80.
Asterias Biotherapeutics (NYSE:AST) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The firm had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $1.25 million. Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%.
TRADEMARK VIOLATION WARNING: This report was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/11/09/zacks-asterias-biotherapeutics-inc-ast-given-8-88-average-target-price-by-brokerages.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.